
姓名:溫鴻雁性別:女政治面貌:民進(jìn)會(huì)員
學(xué)歷:研究生學(xué)位:博士職稱:主任醫(yī)師
博,、碩導(dǎo)師:博士,、碩士生導(dǎo)師
本崗位工作年數(shù):29年
研究方向:風(fēng)濕免疫病及相關(guān)疑難罕見病的臨床和基礎(chǔ)研究
榮譽(yù)稱號(hào):享受國(guó)務(wù)院特殊津貼專家、山西省新興產(chǎn)業(yè)領(lǐng)軍人才,、山西省學(xué)術(shù)技術(shù)帶頭人,、山西省高等學(xué)校“131”領(lǐng)軍人才,、山西省衛(wèi)生健康委“高端領(lǐng)軍人才”,、山西省衛(wèi)生系統(tǒng)百千萬人才、入選國(guó)家級(jí)百千萬人才推薦人選,。
學(xué)術(shù)任職:山西省醫(yī)師協(xié)會(huì)風(fēng)濕病學(xué)分會(huì)會(huì)長(zhǎng),、山西省醫(yī)學(xué)會(huì)罕見病專業(yè)委員會(huì)副主任委員、山西省醫(yī)學(xué)會(huì)罕見病專業(yè)委員會(huì)免疫風(fēng)濕病學(xué)組主任委員,、中華醫(yī)學(xué)會(huì)/中國(guó)醫(yī)師協(xié)會(huì)風(fēng)濕病學(xué)分會(huì)青年委員,、國(guó)家皮膚與免疫臨床醫(yī)學(xué)研究中心硬皮病與肌炎研究委員會(huì)委員、山西省醫(yī)學(xué)會(huì)骨質(zhì)疏松與骨礦鹽專業(yè)委員會(huì)常委,、山西省專家學(xué)者協(xié)會(huì)風(fēng)濕病學(xué)專業(yè)委員會(huì)主任委員,。
近五年承擔(dān)科研課題情況:
1.山西省高等教育“百億工程”科技引導(dǎo)專項(xiàng)-專病隊(duì)列研究:中國(guó)華北地區(qū)系統(tǒng)性硬化癥隊(duì)列研究(2024-隊(duì)列研究-10)
2.山西省自然科學(xué)基金面上項(xiàng)目:m6A甲基化修飾CircRNA介導(dǎo)RANKL/IL-22在類風(fēng)濕關(guān)節(jié)炎中促進(jìn)成纖維滑膜細(xì)胞侵襲和遷移(20210302123268)
3.山西省衛(wèi)生健康委員會(huì)(山西省醫(yī)學(xué)重大科技攻關(guān)專項(xiàng)):m6A閱讀器YTHDF1通過對(duì)Foxp3表達(dá)的翻譯在類風(fēng)濕關(guān)節(jié)炎中調(diào)控Th17/Treg平衡機(jī)制的研究(2021XM08)
4.山西省新興產(chǎn)業(yè)領(lǐng)軍人才基金:RNA m6A甲基化在類風(fēng)濕關(guān)節(jié)炎患者中對(duì)Th17/Treg細(xì)胞平衡機(jī)制的影響及研究(2020創(chuàng)新15)
代表性論著及近五年的代表性論文(限10項(xiàng)以內(nèi)):
1.Yang HD, Cheng H, Dai RR, Shang LL, Zhang XY, Wen HY*. Macrophage polarization in tissue fibrosis. PeerJ. 2023,11:e16092.
2.Cheng H, Yu Z, Yan CL, Yang HD, Gao C, Wen HY*. Long-Term Efficacy and Low Adverse Events of Methylprednisolone Pulses Combined to Low-Dose Glucocorticoids for Systemic Sclerosis: A Retrospective Clinical Study of 10 Years’Follow-Up. Journal of Inflammation Research. 2022,15:4421-4433
3.Cheng H, Zhang XY, Yang HD, Yu Z, Yan CL, Gao C, Wen HY*. Efficacy and safety of belimumab/low-dose cyclophosphamide therapy in moderate-to-severe systemic lupus erythematosus. Front Immunol. 2022,13:911730.
4.Rong-Hong Guo,Hao Cheng,Xiao-Ying Zhang,Zhen Yu,Guang-Hui Wang,Shu-Ya Hao,Xiao-Peng Gao,Hong-Yan Wen*.Changes in peripheral T-lymphocyte subsets and serum cytokines in patients with systemic sclerosis.Front Pharmacol. 2022,13:986199. doi: 10.3389/fphar.2022.986199. eCollection 2022.
5.Yu Z, Cheng H, Ding T, Liang Y, Yan C, Gao C, Wen H*. Absolute decrease in regulatory T cells and low-dose interleukin-2 therapy: restoring and expanding regulatory T cells to treat systemic sclerosis: a 24-week study. Clin Exp Dermatol. 2022 Dec;47(12):2188-2195. doi:10.1111/ced.15345.
6.Yu Z, Cheng H, Liang Y, Ding T, Yan C, Gao C and Wen H*. Decreased Serum 25-(OH)-D Level Associated With Muscle Enzyme and Myositis Specifific Autoantibodies in Patients With Idiopathic Inflflammatory Myopathy. Front. Immunol. 12:642070. doi: 10.3389/fimmu.2021.642070
7.Hao Cheng, Chen-sheng Zhao, Cheng-lan Yan, Chong Gao, Hong-yan Wen*. Efficacy of Belimumab for refractory systemic lupus erythematosus (SLE) involving the central nervous system. Eur J Intern Med. 2021,92:117-120.
8.張少晨,郭容宏,張婷婷,溫鴻雁*.細(xì)胞凋亡在纖維化疾病中調(diào)控作用的研究進(jìn)展[J].中華內(nèi)科雜志,2024,63(7):716-719.
9.張曉英,程浩,于震,楊惠丹,溫鴻雁*.貝利尤單抗聯(lián)合常規(guī)治療對(duì)系統(tǒng)性紅斑狼瘡患者外周血自然殺傷細(xì)胞影響初步探討[J].中華風(fēng)濕病學(xué)雜志,2023,27(6):378-384.
10.郝舒雅,于震,程浩,溫鴻雁*.免疫細(xì)胞對(duì)系統(tǒng)性硬化癥纖維化及發(fā)病機(jī)制的研究進(jìn)展[J].中華風(fēng)濕病學(xué)雜志,2022,26(6):415-420.